Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report issued on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on the company. Wall Street Zen downgraded Sangamo Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 30th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Finally, Barclays lowered their target price on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $4.50.

Sangamo Therapeutics Stock Down 4.2%

Shares of Sangamo Therapeutics stock opened at $0.56 on Tuesday. The company has a market capitalization of $129.95 million, a price-to-earnings ratio of -1.43 and a beta of 1.19. Sangamo Therapeutics has a 12-month low of $0.30 and a 12-month high of $3.18. The firm’s 50-day moving average price is $0.57 and its two-hundred day moving average price is $0.99.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The firm had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative return on equity of 345.98% and a negative net margin of 124.61%. On average, sell-side analysts expect that Sangamo Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Sangamo Therapeutics

Several hedge funds have recently modified their holdings of SGMO. E Fund Management Co. Ltd. bought a new position in Sangamo Therapeutics in the fourth quarter valued at about $25,000. JPMorgan Chase & Co. increased its stake in shares of Sangamo Therapeutics by 679.5% in the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 21,793 shares during the period. PNC Financial Services Group Inc. raised its holdings in Sangamo Therapeutics by 2,319.1% in the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 25,000 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in Sangamo Therapeutics in the 4th quarter valued at approximately $28,000. Finally, Captrust Financial Advisors acquired a new stake in Sangamo Therapeutics during the 4th quarter worth approximately $30,000. Institutional investors and hedge funds own 56.93% of the company’s stock.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.